Search research articles
Contact Us
Filters
Showing results (41-50 of 45) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 45 results.
Science (New York, N.Y.)
|
September 11, 1998
Prevention of cardiac hypertrophy in mice by calcineurin inhibition
M A Sussman, H W Lim, N Gude, et al.
Archiv Der Pharmazie
|
November 26, 2002
Synthesis and biological evaluation of cytotoxic 6(7)-alkyl-2-hydroxy-1, 4-naphthoquinones
José M Miguel del Corral, Maria Angeles Castro, Marina Gordaliza, et al.
Molecular Genetics and Metabolism
|
June 8, 2002
Macrophage inducible nitric oxide synthase gene expression is blocked by a benzothiophene derivative with anti-HIV properties
M Carballo, M Conde, J Tejedo, et al.
British Journal of Cancer
|
November 25, 2010
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
A Gualberto, M L Hixon, D D Karp, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 45) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 45 results.
Science (New York, N.Y.)
|
September 11, 1998
Prevention of cardiac hypertrophy in mice by calcineurin inhibition
M A Sussman, H W Lim, N Gude, et al.
Archiv Der Pharmazie
|
November 26, 2002
Synthesis and biological evaluation of cytotoxic 6(7)-alkyl-2-hydroxy-1, 4-naphthoquinones
José M Miguel del Corral, Maria Angeles Castro, Marina Gordaliza, et al.
Molecular Genetics and Metabolism
|
June 8, 2002
Macrophage inducible nitric oxide synthase gene expression is blocked by a benzothiophene derivative with anti-HIV properties
M Carballo, M Conde, J Tejedo, et al.
British Journal of Cancer
|
November 25, 2010
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
A Gualberto, M L Hixon, D D Karp, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
Page
of 5